Literature DB >> 21514482

Interventions to promote adherence with oral agents.

Susan M Schneider1, Kimberly Hess, Tracy Gosselin.   

Abstract

OBJECTIVES: The advent of oral therapies has dramatically changed the landscape of cancer therapy. Yet the degree to which patients actually take the prescribed agents as ordered remains unknown. This article outlines the challenges that oral chemotherapy agents present to both patients and providers and suggests interventions for promoting adherence. DATA SOURCES: Published articles and web resources.
CONCLUSION: Barriers and facilitators to medication adherence are reviewed and interventions to promote medication adherence are presented. Strategies that include patient education and symptom management can promote adherence. IMPLICATIONS FOR NURSING PRACTICE: Maximizing adherence to oral chemotherapy agents can have many positive outcomes, but most important is improvement in overall survival and life expectancy. Other outcomes include improved safety and quality of life. Patients risk improper dosing and an increase in disease recurrence when there is nonadherence with medications. Correct dosing, education, and symptom management are all critical to ensuring adherence. Nursing interventions that incorporate education, early symptom identification, and reminder prompts can improve outcomes.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21514482      PMCID: PMC3653175          DOI: 10.1016/j.soncn.2011.02.005

Source DB:  PubMed          Journal:  Semin Oncol Nurs        ISSN: 0749-2081            Impact factor:   2.315


  49 in total

1.  The importance of medication adherence in improving chronic-disease related outcomes: what we know and what we need to further know.

Authors:  Rajesh Balkrishnan
Journal:  Med Care       Date:  2005-06       Impact factor: 2.983

2.  Importance of calcium co-medication in bisphosphonate therapy of osteoporosis: an approach to improving correct intake and drug adherence.

Authors:  Johann D Ringe; Stefan A P van der Geest; Gerd Möller
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 3.  Adherence to therapy with oral antineoplastic agents.

Authors:  Ann H Partridge; Jerry Avorn; Philip S Wang; Eric P Winer
Journal:  J Natl Cancer Inst       Date:  2002-05-01       Impact factor: 13.506

4.  Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study.

Authors:  J Y Lee; J W Kusek; P G Greene; S Bernhard; K Norris; D Smith; B Wilkening; J T Wright
Journal:  Am J Hypertens       Date:  1996-08       Impact factor: 2.689

5.  Patient preferences for oral versus intravenous palliative chemotherapy.

Authors:  G Liu; E Franssen; M I Fitch; E Warner
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

6.  Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer.

Authors:  E L Mayer; A H Partridge; L N Harris; R S Gelman; S T Schumer; H J Burstein; E P Winer
Journal:  Breast Cancer Res Treat       Date:  2009-03-18       Impact factor: 4.872

7.  Gender differences in psychosocial profile at entry into cardiac rehabilitation.

Authors:  V Brezinka; E Dusseldorp; S Maes
Journal:  J Cardiopulm Rehabil       Date:  1998 Nov-Dec       Impact factor: 2.081

Review 8.  Safe practices and financial considerations in using oral chemotherapeutic agents.

Authors:  Sylvia B Bartel
Journal:  Am J Health Syst Pharm       Date:  2007-05-01       Impact factor: 2.637

9.  Improved adherence and outcomes for pediatric liver transplant recipients by using text messaging.

Authors:  Tamir Miloh; Rachel Annunziato; Ronen Arnon; Jill Warshaw; Sanobar Parkar; Frederick J Suchy; Kishore Iyer; Nanda Kerkar
Journal:  Pediatrics       Date:  2009-10-12       Impact factor: 7.124

Review 10.  A changing paradigm for cancer treatment: the advent of new oral chemotherapy agents.

Authors:  Cindi Holt Bedell
Journal:  Clin J Oncol Nurs       Date:  2003 Nov-Dec       Impact factor: 1.027

View more
  18 in total

1.  Patients' Perception of App-based Educational and Behavioural Interventions for Enhancing Oral Anticancer Medication Adherence.

Authors:  Eskinder Eshetu Ali; Jo Lene Leow; Lita Chew; Kevin Yi-Lwern Yap
Journal:  J Cancer Educ       Date:  2018-12       Impact factor: 2.037

2.  Effectiveness of a nurse-led telephone follow-up in the therapeutic management of patients receiving oral antineoplastic agents: a randomized, multicenter controlled trial (ETICCO study).

Authors:  Wafa Bouleftour; Thierry Muron; Aline Guillot; Fabien Tinquaut; Romain Rivoirard; Jean-Philippe Jacquin; Léa Saban-Roche; Karima Boussoualim; Emmanuelle Tavernier; Karine Augeul-Meunier; Olivier Collard; Benoite Mery; Sidonie Pupier; Mathieu Oriol; Aurélie Bourmaud; Pierre Fournel; C Vassal
Journal:  Support Care Cancer       Date:  2021-01-07       Impact factor: 3.603

3.  Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer.

Authors:  Giuseppe L Banna; Valeria Urzia; Chiara Benanti; Alessandra Pitrè; Helga Lipari; Rosario Di Quattro; Ugo De Giorgi; Giuseppe Schepisi; Umberto Basso; Davide Bimbatti; Francesco Rundo; Massimo Libra; Lorenzo Malatino
Journal:  Support Care Cancer       Date:  2020-01-20       Impact factor: 3.603

4.  Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial.

Authors:  Olivier Mir; Marie Ferrua; Aude Fourcade; Delphine Mathivon; Adeline Duflot-Boukobza; Sarah Dumont; Eric Baudin; Suzette Delaloge; David Malka; Laurence Albiges; Patricia Pautier; Caroline Robert; David Planchard; Stéphane de Botton; Florian Scotté; François Lemare; May Abbas; Marilène Guillet; Vanessa Puglisi; Mario Di Palma; Etienne Minvielle
Journal:  Nat Med       Date:  2022-04-25       Impact factor: 87.241

Review 5.  The Association Between Patient-Reported and Objective Oral Anticancer Medication Adherence Measures: A Systematic Review
.

Authors:  Thomas M Atkinson; Vivian M Rodríguez; Mallorie Gordon; Isabelle K Avildsen; Jessica C Emanu; Sarah T Jewell; Kimberly A Anselmi; Pamela K Ginex
Journal:  Oncol Nurs Forum       Date:  2016-09-01       Impact factor: 2.172

6.  The association between patients' perceived continuity of care and beliefs about oral anticancer treatment.

Authors:  Orit Cohen Castel; Efrat Shadmi; Lital Keinan-Boker; Tal Granot; Khaled Karkabi; Efrat Dagan
Journal:  Support Care Cancer       Date:  2019-01-28       Impact factor: 3.603

7.  Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia.

Authors:  Chan Shen; Bo Zhao; Lei Liu; Ya-Chen Tina Shih
Journal:  Cancer       Date:  2017-10-04       Impact factor: 6.860

8.  Patients' Perceived Continuity of Care and Adherence to Oral Anticancer Therapy: a Prospective Cohort Mediation Study.

Authors:  Orit Cohen Castel; Efrat Dagan; Lital Keinan-Boker; Marcelo Low; Efrat Shadmi
Journal:  J Gen Intern Med       Date:  2021-03-25       Impact factor: 6.473

9.  Oral self-management of palbociclib (Ibrance®) using mobile technology protocol.

Authors:  Ann M Mazzella Ebstein; Margaret Barton-Burke; Venice Anthony; Andrea Smith; Zhigang Zhang; Mark Robson
Journal:  J Adv Nurs       Date:  2020-11-27       Impact factor: 3.187

10.  Adherence management for patients with cancer taking capecitabine: a prospective two-arm cohort study.

Authors:  Linda Krolop; Yon-Dschun Ko; Peter Florian Schwindt; Claudia Schumacher; Rolf Fimmers; Ulrich Jaehde
Journal:  BMJ Open       Date:  2013-07-19       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.